Preoperative carbohydrate antigen 19.9 level predicts lymph node metastasis in resectable adenocarcinoma of the head of the pancreas: a further plea for biological resectability criteria
Authors:
- Alessandro CoppolaAlessandro Coppola
- Vincenzo La VaccaraVVVincenzo La Vaccara
- Tommaso FarolfiTFTommaso Farolfi
- Horacio J. AsbunHAHoracio J. Asbun
- Ugo BoggiUBUgo Boggi
- Kevin ConlonKCKevin Conlon
- Bjørn EdwinBEBjørn Edwin
- Cristina FerroneCFCristina Ferrone
- Eduard JonasEJEduard Jonas
- Norihiro KokudoNKNorihiro Kokudo
- Sohei SatoiSohei Satoi
Open Access
- 22 September 2023
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (10) , 6092-6099
Abstract
Introduction: Lymph-nodal involvement (N+) represents an adverse prognostic factor after pancreatoduodenectomy (PD) for pancreatic adenocarcinoma (PDAC). Preoperative diagnostic and staging modalities lack sensitivity for identifying N+. This study aimed to investigate preoperative carbohydrate antigen 19.9 (CA 19.9) in predicting the N+ stage in resectable-PDAC (R-PDAC). Methods: Patients included in a multi-institutional retrospective database of PDs performed for R-PDAC from January 2000 to June 2021 were analysed. A preoperative laboratory value of CA 19.9 greater than 37 U/l was used in univariate and multivariate logistic regression analysis to determine a possible association with N+. Additionally, different cut-offs of CA 19.9 related to the preoperative clinical T (cT) stage was assessed to evaluate the risk of N+. Results: A total of 2034 PDs from thirteen centres were included in the study. CA 19.9 greater than 37 U/l was significantly associated with higher N+ at univariate and multivariate analysis (P<0.001). CA 19.9 levels greater than 37 U/l were associated with N+ in 75.9%, 81.3%, and 85.7% of patients, respectively, in cT1, cT2, and cT3 tumours and with higher cut-off values for all cT stages. Conclusion: Lymph-nodal involvement is strongly related to preoperative CA 19.9 levels. Specially in patients staged as cT3 the CA 19.9 could represent a valid and easy tool to suspect nodal involvement. Due to these findings, R-PDAC patients with elevated CA 19.9 values should be considered in a more biologically advanced stage.Keywords
This publication has 21 references indexed in Scilit:
- Accuracy of various criteria for lymph node staging in ductal adenocarcinoma of the pancreatic head by computed tomography and magnetic resonance imagingWorld Journal of Surgical Oncology, 2020
- Cancer outcomes are independent of preoperative CA 19‐9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysisJournal of Surgical Oncology, 2020
- Actual Five-year Survival After Upfront Resection for Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 2020
- Diagnostic Value of CA 19-9 and Carcinoembryonic Antigen for Pancreatic Cancer: A Meta-AnalysisGastroenterology Research and Practice, 2018
- Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 2018
- International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017Pancreatology, 2018
- Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database StudyJournal of the American College of Surgeons, 2016
- Pancreatic cancerThe Lancet, 2016
- Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: A consensus statement by the International Study Group on Pancreatic Surgery (ISGPS)Surgery, 2014
- Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)Surgery, 2014